

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human IL-6 in direct ELISAs. Does not cross-react with recombinant IL-6 from mouse, rat, or pig.
Source	Monoclonal Mouse IgG _{2B} Clone # 1936
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human IL-6 Val30-Met212 Accession # P05231
Endotoxin Level	<0.20 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS and NaCl with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Immunocytochemistry	8-25 µg/mL	See Below
Intracellular Staining by Flow Cytometry	0.25 µg/10 ⁶ cells	See Below
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
Neutralization	Measured by its ability to neutralize IL-6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. The Neutralization Dose (ND ₅₀) is typically 0.05-0.15 µg/mL in the presence of 2.5 ng/mL Recombinant Human IL-6.	


DATA

Immunocytochemistry




IL-6 in Human PBMCs. IL-6 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with LPS and monensin using Mouse Anti-Human IL-6 Monoclonal Antibody (Catalog # MAB2061) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (yellow; Catalog # NL007) and counterstained with DAPI (blue). View our protocol for [Fluorescent ICC Staining of Non-adherent Cells](#).

Intracellular Staining by Flow Cytometry



Detection of IL-6 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with 100 µg/mL LPS for 24 hours were stained with Mouse Anti-Human IL-6 Monoclonal Antibody (Catalog # MAB2061, filled histogram) or isotype control antibody (Catalog # MAB004, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer 1 (Catalog # FC005). View our protocol for [Staining Intracellular Molecules](#).

Neutralization



Cell Proliferation Induced by IL-6 and Neutralization by Human IL-6 Antibody. Recombinant Human IL-6 (Catalog # 206-IL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL-6 (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-6 Monoclonal Antibody (Catalog # MAB2061). The ND₅₀ is typically 0.05-0.15 µg/mL.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin 6 (IL-6) is a pleiotropic α -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22-28 kDa phosphorylated and variably glycosylated molecule (1-4). Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6 (5). Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (6-9). Human IL-6 is equally active on mouse and rat cells (10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 13).

References:

1. Van Snick, J. (1990) *Annu. Rev. Immunol.* **8**:253.
2. Hodge, D.R. *et al.* (2005) *Eur. J. Cancer* **41**:2502.
3. Jones, S.A. (2005) *J. Immunol.* **175**:3468.
4. Rose-John, S. *et al.* (2006) *J. Leukoc. Biol.* **80**:227.
5. Hirano, T. *et al.* (1986) *Nature* **324**:73.
6. Alberti, L. *et al.* (2005) *Cancer Res.* **65**:2.
7. Kestler, D.P. *et al.* (1995) *Blood* **86**:4559.
8. Kestler, D.P. *et al.* (1999) *Am. J. Hematol.* **61**:169.
9. Bihl, M.P. *et al.* (2002) *Am. J. Respir. Cell Mol. Biol.* **27**:48.
10. Chiu, C.P. *et al.* (1988) *Proc. Natl. Acad. Sci. USA* **85**:7099.
11. Murakami, M. *et al.* (1993) *Science* **260**:1808.
12. Muller-Newen, G. (2003) *Sci. STKE* **2003**:PE40.
13. Mitsuyama, K. *et al.* (2006) *Clin. Exp. Immunol.* **143**:125.